Coronary microvascular dysfunction during pregnancy is linked to adverse pregnancy outcomes and future cardiovascular risk, but no prospective trials have evaluated diagnostic or treatment strategies specific to this population.
Coronary microvascular dysfunction (CMD) is increasingly recognized as a significant cardiovascular condition, particularly among women, yet its diagnosis and management during pregnancy remain poorly understood. CMD may arise de novo in the context of hypertensive disorders of pregnancy or represent an exacerbation of pre-existing endothelial dysfunction. This article views current evidence surrounding CMD in pregnancy, outlines the limitations of current diagnostic and treatment approaches, and highlights critical research gaps that must be addressed to improve outcomes in this vulnerable population.
Beneki et al. (Tue,) conducted a review in Coronary microvascular dysfunction in pregnancy. Coronary microvascular dysfunction during pregnancy is linked to adverse pregnancy outcomes and future cardiovascular risk, but no prospective trials have evaluated diagnostic or treatment strategies specific to this population.